Clinical trial • Phase I • Oncology

Lutetium-177 DOTA-TATE for Somatostatin receptor-positive tumours

Phase I trial of Lutetium-177 DOTA-TATE for Somatostatin receptor-positive tumours. 18 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Somatostatin receptor-positive tumours
Trial Stage
Phase I
Drug Modality
Radiopharmaceutical|Small molecule

Key dates

Initial CTIS Submission Date
24-09-2024
First CTIS Authorization Date
23-10-2024

Trial design

Phase I trial across 1 site in Sweden.

Target Sample Size
18

Eligibility

Recruits 18 Vulnerable populations not selected; no consent or assent information provided..

Vulnerable Population
Vulnerable populations not selected; no consent or assent information provided.

Recruitment

Planned Sample Size
18
Recruitment Window Months
101

Geography

Total Number Of Sites
1
Total Number Of Participants
18

Sweden

Earliest CTIS Part Ii Submission Date
07-10-2024
Latest Decision Or Authorization Date
23-10-2024
Processing Time Days
16
Number Of Sites
1
Number Of Participants
18

Sites

Site Name
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Department Name
Oncology
Principal Investigator Name
Andreas Hallqvist
Principal Investigator Email
andreas.hallqvist@vgregion.se
Contact Person Name
Andreas Hallqvist
Contact Person Email
andreas.hallqvist@vgregion.se
Number Of Participants
18

Sponsor

Primary sponsor

Full Name
Vaestra Goetalandsregionen
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
177Lu-DOTA-TATE
Active Substance
Lutetium-177 DOTA-TATE
Modality
Radiopharmaceutical
Investigational Product Name
olaparib
Active Substance
olaparib
Modality
Small molecule
Combination Treatment
Yes

Related trials

Other published trials that may interest you.